# Celiac Disease FDA approvals and PDUFA dates

Canonical: https://sec-api.dev/indications/celiac-disease

> No upcoming FDA catalysts in celiac Disease; 6 past events are recorded.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| December 9, 2025 | [TAK-101 primary completion](https://sec-api.dev/pdufa/tak-101) | TAK | Celiac Disease | completed | "NCT04530123 (Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-09 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530123)) |
| September 2, 2026 | [TEVA PHARMACEUTICAL INDUSTRIES LTD topline data readout](https://sec-api.dev/companies/teva/catalysts) | TEVA | Celiac disease | completed, positive | "On September 2, 2026, Teva announced positive topline results from an ongoing Phase 2a study of TEV-'408, in adults with Celiac disease." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/818686/000081868626000006/teva-20260930.htm)) |
| October 2, 2026 | [Tev-53408 dose a primary completion](https://sec-api.dev/pdufa/tev-53408) | TEVA | Celiac Disease | completed | "NCT06807463 (A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-02 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807463)) |
| Oct 2026 to Jan 2027 | [Tev-53408 dose a topline data readout](https://sec-api.dev/pdufa/tev-53408) | TEVA | Celiac Disease | scheduled | "NCT06807463 (A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-10-02 (ACTUAL); Lead Sponsor Teva Branded Pharmaceutical Products R&D LLC." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06807463)) |
| October 6, 2026 | [TAK-101 topline data readout](https://sec-api.dev/pdufa/tak-101) | TAK | Celiac Disease | completed | "NCT04530123 (Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-12-09 (ACTUAL); Lead Sponsor Takeda; Results First Posted 2026-10-06." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04530123?tab=results)) |
| October 8, 2026 | [FB102 topline data readout](https://sec-api.dev/pdufa/fb102) | ARGX | celiac disease | completed, positive | "Amsterdam, the Netherlands - argenx SE (Euronext & Nasdaq: ARGX), a global immunology innovation company, today announced positive topline results from the Phase 2 study evaluating FB102, a first-in-class CD122 inhibitor, in adults with celiac disease." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1697862/000110465926114491/tm2627263d1_ex99-1.htm)) |

## Drugs

- [TAK-101](https://sec-api.dev/pdufa/tak-101) (TAK)
- [Tev-53408 dose a](https://sec-api.dev/pdufa/tev-53408) (TEVA)
- [FB102](https://sec-api.dev/pdufa/fb102) (ARGX)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/indications/celiac-disease.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Celiac Disease FDA approvals and PDUFA dates." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/indications/celiac-disease

```bibtex
@misc{secapidev_indications_celiac_disease_20261116,
  title        = {Celiac Disease FDA approvals and PDUFA dates},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/indications/celiac-disease}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_indications_celiac_disease_20261116","title":"Celiac Disease FDA approvals and PDUFA dates","publisher":"sec-api.dev","URL":"https://sec-api.dev/indications/celiac-disease","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
